Defense Tech: Warhound Secures $200M to Clone Elite Military Canines

Warhound, a new biotechnology firm, has raised $200 million to create a new line of military dogs through genetic editing and cloning. The company aims to produce animals with superior health and performance traits for use by the US military and other first responder agencies.

The venture is a joint effort involving Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. Lamm confirmed that the team has begun editing genes from cell samples taken from high-performing donor dogs. These donors include Belgian Malinois, labradors, and shepherds currently serving in military, police, and first responder roles across the United States.

The initial scientific focus is on reducing the likelihood of common breed-specific ailments, such as hip dysplasia and certain cancers. Lamm indicated to TechCrunch that future genetic modifications could enhance physical capabilities, potentially making the dogs faster, more agile, or better equipped to detect scents.

The founders bring specific expertise to the project. Luckey, who previously founded Oculus VR, leads Anduril, a defense company that won a US Army contract for battlefield intelligence systems. Lamm’s Colossal Biosciences is known for its de-extinction projects, including efforts to revive the dire wolf and woolly mammoth.

Anduril’s contribution is limited to hardware and software. The company will design protective gear for the dogs, including goggles, vests, and body armor, rather than integrating robotic components. The ownership structure separates the founders from the equity; Luckey is a partner but does not hold a stake, while Colossal Biosciences does. David Spirk, a former Palantir executive, serves as CEO.

The first batch of these genetically engineered dogs is scheduled to be born in early 2027. Once born, the animals will undergo training for standard working roles, including bomb detection and search-and-rescue operations.